| Revenue growth | Q2 -9% YoY; H1 -12% YoY |
|---|---|
| Margins | Op EBITDA 18% vs 22% YoY; mid-20s ex-forex |
| Demand visibility | First Bayview biologics manufacturing agreement signed |
Growth
Q2 revenue Rs 833 Cr, down 9% YoY; H1 Rs 1,569 Cr, down 12%. Q2 operating EBITDA Rs 147 Cr, down 26% YoY.
Outlook
No numeric guidance. Cost-optimisation benefits expected in coming quarters. Bayview drug-substance manufacturing planned next year.
Risks
Forex hedge losses (Rs 61 Cr in Q2) compressed margins. Revenue and profit still declining YoY.
Investor Presentation filed with NSE, NSE: SYNGENE. Summary written with AI assistance from the document.
Syngene International Ltd: key numbers
- Share price
- ₹410.85
- Market cap
- ₹16,585 Cr
- Revenue (annual)
- ₹3,739 Cr
- Net profit (annual)
- ₹316.7 Cr
- P/E (TTM)
- 89.1×Sector 46.1×
- Promoter holding
- 52.59%+0.00% QoQ
- FII holding
- 10.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Syngene International Ltd
All →Syngene International Earnings Call Transcript: Key Takeaways
Syngene reports a transitional quarter with sequential recovery but YoY declines due to the absence of the large Librela revenue stream.
Syngene International Results Update
Syngene reported Q2 FY27 revenue of Rs 833 Crore, up 13% sequentially, with PAT of Rs 32 Crore. Release includes P&L highlights and business updates.
Syngene International Management Change
Syngene reports changes in senior management: two heads move from SMP to Non-SMP, Ajay Tandon resigns effective October 30, 2026, and CFO Deepak Jain plans to leave. The CFO is a KMP, so this is a material leadership change.
Syngene International Q2 FY27 Results: Net Profit ₹32.2 Cr, Down 52.0% YoY
Syngene International Ltd reported revenue from operations of ₹832.7 Cr (-8.6% YoY) and net profit of ₹32.2 Cr (-52.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹32.2 Cr · -52.0% YoY
Syngene International Other Announcement
Syngene International Limited has submitted the quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.
Syngene International Board Meeting Date
Syngene International Limited will hold a board meeting on October 27, 2026, to approve the standalone and consolidated financial results for the quarter ended September 30, 2026.